you much, Thank everyone. today. Good Thank very morning, joining for you Francesca. us
was and Pfizer. were and on we company. in our performance our by pleased the of year I'm We with for priorities, a executing exceeded progress strengthen we made clear while for strategic our or also that delivering strong guided met transformative goals XXXX one, execution each financial changes commitments.
decade, we oncology one best successfully made we of First, the past industry. one in largest Seagen integrated creating the companies have the business, in the of investments the
transform one upgrade done to our They to power marketing our job company a to and external global of leaders engine. increase Malik divisions, U.S. our split X focus we in advertising and de operations and senior have agencies AI the and XXXX, our Germay selling Alexandre X appointed Aamir of into down commercial start the At both. powerhouse international, leveraged and consolidated to tremendous commercial commercial capabilities.
brand communications New data-driven have social field on effectiveness some commercial in of and resources, deployment commercial commercial increased significantly the the medical that elevation and micro-targeting and medical precision are investment. of our returns and in Pfizer our media of strategies
We impact ranking earned actions in and in the or top to recognition XXXX position #X of performance leaders. the in we strong in the market the our financial are our specialties claim of and the Force report Field of XX% focus. IQVIA these our improved seeing We X spot in Ranking which U.S.
empowers a study to with X our III This and the fully of its and tapping company operate end-to-end very progress under into discovery I'm than starts strong while approvals, R&D our on development. X focus Boshoff oncology, and inflammation structure Chris also engine create units more X vaccines, moved can of enterprise-wide immunology. proud fast year agility pivotal as a key AI-powered and that and pipeline R&D in our capabilities medicine such of units drug internal focused research biotech differentiated a excited dozen XXXX, leaders. Phase changes with including in new I'm readouts.
with $XX financial delevering returning And shareholder has programs, capital deployed strategically after results. of dividends. of directly shareholders we good by realign on our year also enhance billion discipline to to margins and investing ended base. in R&D focus $X.X cost the Our actions yielded value, through to our series internal $X.X support nearly expanded We a billion billion
strong commitment Finally, we also reinforced our governance. to
of these created and shareholder Board new in changes a strength. X creation. from markets financial new year to foundation All strong expertise value allow Our us a deep have start bring position members and the
margin R&D we our XXXX, emphasis improving excellence effectiveness. focus productivity, the commercial emphasis and move priorities. Last In capital about So on had now will significant allocation. year, let to shareholder-friendly commercial our a on expansion, while XXXX speak maintaining me improving
me us possibility XX Phase have including new we ahead up to expect starts. a with III X year strong X least R&D potential we readouts our potential of R&D. of of at decisions, catalysts believe milestones, pipeline, multiple pivotal and the key Let regulatory start organization our Across program to achieve and
we For atirmociclib, cancer. metastatic with CDKX study inhibitor candidate, our highly selective example, next-generation, in III in our first-line a first patient yesterday, breast dosed Phase
first-line We with also we combination ER Arvinas. anticipate starting codeveloping in study are with degrader the an vepdegestrant, additional
cell this Phase in non-small Our study to ADC year, III expect its lung in sigvotatug continues And III we study start cancer. vedotin Phase first-line and a second-line cancer. cell non-small
vedotin first-line is non-small metastatic and second-line-plus Phase cell begin candida, year, the where PD-LX and head studies need potential cancer ADC first-in-class ADC, a X neck this expected one in significant. III is lung to PDLXV unmet squamous carcinoma targeting in Our one cell
myeloma triple a would readout and expanding exposed robust a population have clinical versus program aimed year, myeloma, anticipate indications the the of indication. We ELREXFIO that, and III successful multiple if the multiple we currently development at this approved approved, study in class in relapsed/refractory addressable double Phase
PCV-XX vaccine that study expect for we bridge year, serotypes. expect help vaccines, candidate we start This this could III Phase the Phase In a This us to candy. than more XX serotypes. to accelerate for diff PCV and is C. covering fifth XX III our with covering important also study our candidate progress to our start year generation foundational work
this In an of track internal on of the of to quarter optimization in provide danuglipron upgrade our dose year. we remain first studies medicine,
ibuzatrelvir, study year oral and candidate, study. COVID-XX For a III ponsegromab, start cachexia, to expect this cancer continues its Phase pivotal in antiviral our second-generation we
X potential antibodies medicines Within tri-specific Phase I&I, we continue that a II. of to currently in first-in-class progress include portfolio
execution commercial by we impact products for our our launched our market of in and the a pleased portfolio. and strong with I gaining progress core newly strength several commercial brands. was will of maintaining performance our improving our year of XXXX start strategy. are highlighting and of and discuss let's oncology share Now
#X urothelial prescribed become treatment locally first-line plus PADCEV already metastatic advanced the U.S. growth pembrolizumab in driver an has as the is important for it cancer
this data which, interim registrational cancer, studies patients nearly in potential from U.S. pivotal the triple addressable bladder ongoing successful total muscle-invasive expecting year the in if approved, would and are We
operational position clinically worldwide which growth BRAFTOVI mFOLFOXX expanded with patients hardest and mutation. colorectal are BRAF in with year-over-year XX% a achieved meaningful cancer overall of treat in showed with some that statistically significant the announced in improvement leadership and combination its in we survival to multiple survival cetuximab tumors, Yesterday, cancer. BRAFTOVI/MEKTOVI progression-free VXXXE and BRAF metastatic
improvement as is potential the to a conference.
LORBRENA, PFS care operational setting. year-over-year for achieved excited are lung this adults cell forward OS with and XX% looking first-line with scientific We of worldwide are robust a very cancer, in in metastatic in standard presenting data a non-small ALK-positive the and emerging growth and treatment
year myeloma seen more Following double-digit in strong of our in last or X share first-line full States.
I and share alive the without million the in had with new also $XXX overall XXXX with in the in than within patients trial triple-class-exposed want BCMA-directed refractory for starts disease of increase data relapse June's CROWN revenue portfolio. COVID-XX class to a increasing performance unprecedented after about LORBRENA United patient and multiple prescribers.
ELREXFIO showing antibodies has patients bispecific comment progression years, both XX% new a were
relatively and strong a of see the stabilizing in see to levels. in disease Paxlovid same U.S. disease continue between utilization. low with stabilizing burden COVID-XX patterns the rates We correlation patterns We the at burden vaccination
our year-over-year XXXX have category, multiyear and amyloid continue core on and operational and to assumptions and of XX% XXXX for access continuing growth. cardiomyopathy.
Eliquis are confident continue for leadership is business.
In position par in We we another is prescribed -- a are VYNDAQEL contracts with patients its anticoagulant drove to of products U.S. in brand to international we Pfizer COVID-XX more international growth our to diagnosing this patterns. with Our with XX% growing transthyretin key growth that and improving And portfolio the treatment year-over-year be millions contributor with the a market. secured in our achieved strengthen this XX% predictable will for from XXXX markets. to a markets, durable oral in momentum family worldwide we in operational progress It patients
leader for the about year-over-year with are opportunities see share, for used we market We NURTEC growth. for continued commercial driven worldwide with with class treating a momentum growth, XX% preventing the CGRP by positive XX% is ongoing and in and pleased strong execution. migraine NURTEC also operational oral
vaccines, respiratory also XX, PREVNAR and ABRYSVO key Our are commercial portfolio. products our in
total we a for adult market rates leadership achieved season in see retain for shipped strong in by to the RSV ability for with position ABRYSVO a our an driven commercial and decrease in vaccination even share, approximately a the market in market have in through confident indication. the older increase reduction U.S. in We volume, adult the doses as percentage execution points our position remain XX
well our to of indication markets. ABRYSVO's our to and season.
With Europe and as progress strong across positioned key adult market We are PREVNAR strong international also revenues, season-to-date sustained have pediatric vaccination approximately X/X the Globally, positive with seeing make for nearly America we momentum last the for rate we U.S. achieved indication. XX% also that indications. cumulative demand share in compared accounts tripled a regions such are confident maternal over market leadership are in in Latin and PREVNAR, for maternal we continue the for key
disease are one potentially States will in at migraine, key We PCV-XX serotype XXXX oncology, I strong I&I.
With we in with in it categories improving PCV of position are commercial in on to in Phase candidate and in opportunities demonstrated next-generation our adults leadership space by achieve earlier. approximately Europe.
Across that, to XX% are largest we for In of and excellence contributors confident our disease portfolio, encouraged build aged commercial our XXXX, our over our the mentioned a older we to vaccines success X, and XX of Dave. maintain the and the United that I, turn invasive of cardiovascular, immunogenicity